The association of glucose metabolism measures and diabetes status with Alzheimer's disease biomarkers of amyloid and tau: A systematic review and meta-analysis

Identificador:  imarina:9368621

Handle: https://hdl.handle.net/20.500.11797/imarina9368621

Autores:  van Gils, Veerle; Rizzo, Marianna; Cote, Jade; Viechtbauer, Wolfgang; Fanelli, Giuseppe; Salas-Salvado, Jordi; Wimberley, Theresa; Bullo, Monica; Fernandez-Aranda, Fernando; Dalsgaard, Soren; Visser, Pieter Jelle; Jansen, Willemijn J; Vos, Stephanie J B

Resumen:
Conflicting evidence exists on the relationship between diabetes mellitus (DM) and Alzheimer's disease (AD) biomarkers. Therefore, we conducted a random-effects meta-analysis to evaluate the correlation of glucose metabolism measures (glycated hemoglobin, fasting blood glucose, insulin resistance indices) and DM status with AD biomarkers of amyloid-beta and tau measured by positron emission tomography or cerebrospinal fluid. We selected 37 studies from PubMed and Embase, including 11,694 individuals. More impaired glucose metabolism and DM status were associated with higher tau biomarkers (r=0.11[0.03-0.18], p=0.008; I2=68%), but were not associated with amyloid-beta biomarkers (r=-0.06[-0.13-0.01], p=0.08; I-2=81%). Meta-regression revealed that glucose metabolism and DM were specifically associated with tau biomarkers in population settings (p=0.001). Furthermore, more impaired glucose metabolism and DM status were associated with lower amyloid-beta biomarkers in memory clinic settings (p=0.004), and in studies with a higher prevalence of dementia (p